Navigation Links
Isis Reports Financial Results and Highlights for Second Quarter of 2008

r expenses associated with the expansion of the companies' programs and, for Isis' GAAP results, an increase in non-cash stock compensation expense reflecting the increase in Isis' stock price over the same periods. The reconciliation of pro forma and GAAP measures is explained later in this release.


Total revenue for the three and six months ended June 30, 2008 of $33.0 million and $54.3 million, respectively, was significantly higher than the revenue from the same periods in 2007 of $3.8 million and $6.3 million as a result of Isis' new collaborations. As part of Isis' strategic relationship with Genzyme Corporation, in the first quarter of 2008 Genzyme purchased $150 million of Isis stock at $30 per share and in the second quarter paid Isis a licensing fee of $175 million. Isis is amortizing the premium on the stock and the license fee into revenue through June 2012. Additionally, in the second quarter of 2008, Isis continued to recognize significant value from its partnerships, satellite companies and subsidiaries including:
-- $2.0 million milestone payment from Bristol-Myers Squibb for a PCSK9

development candidate

-- $4.6 million from Alnylam Pharmaceuticals, Inc.

-- $1.4 million from Antisense Therapeutics Limited

-- $3.3 million from Ibis representing a 72% increase from second half of


-- $656,000 of revenue from Regulus primarily from its GlaxoSmithKline

(GSK) alliance

Operating Expenses

On a pro forma basis, operating expenses for the three and six months ended June 30, 2008 were $32.1 million and $58.5 million, respectively, compared to $21.1 million and $42.1 million for the same periods in 2007. The increase in operating expenses year over year is due to Isis' expanded clinical development programs as its drugs advance in development, an increase in Ibis' operating expenses to support the growth of its commercial business and the activities to

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related biology technology :

1. Barr Reports Second Quarter 2008 GAAP Earnings of $0.52 Per Share; Adjusted Earnings of $0.64 Per Share
2. PAREXEL Reports Fourth Quarter and Fiscal Year 2008 Financial Results
3. Caliper Life Sciences Reports Second Quarter 2008 Results
4. Watson Pharmaceuticals Reports Second Quarter 2008 Results
5. EntreMed Reports Second Quarter 2008 Financial Results
6. Transgenomic Reports Second Quarter 2008 Results
7. Onyx Pharmaceuticals Reports Second Quarter and Six-Month 2008 Financial Results
8. Bionovo Reports Second Quarter 2008 Financial Results
9. AtriCure Reports Record Second Quarter 2008 Financial Results
10. AMICAS Reports Financial Results for the Second Quarter Ended June 30, 2008
11. eResearchTechnology Reports Second Quarter 2008 Results
Post Your Comments:
(Date:10/8/2015)... Oct. 8, 2015  ATCC, the premier global biological ... has been selected by The Michael J. Fox Foundation ... to academic, pharmaceutical, and biotechnology organizations committed to speed ... the United States , and more than 5 ... the United States , and more than 5 ...
(Date:10/8/2015)... Maryland , October 8, 2015 ... .   --> Goldman Small ... in the small cap and microcap sectors, announced ... research report on PharmaCyte Biotech, Inc. (OTCQB - ... focused on developing and preparing treatments for cancer ...
(Date:10/8/2015)... WILMINGTON, Del. , Oct. 8, 2015 /PRNewswire/ ... of CRISPR-Cas technologies for genome editing, jointly announced ... DuPont and Caribou have cross-licensed their respective patent portfolios, ... CRISPR-Cas technology applications in major row crops, and ... applications. --> ...
(Date:10/8/2015)... , Oct. 8, 2015  Today the Wyss Institute ... launch of its start-up company Opsonix Inc. ... Harvard,s Office of Technology Development (OTD) and ... sepsis therapy for clinical use. ... least a million people every year in the U.S. ...
Breaking Biology Technology:
... Corp.,(Nasdaq: GENZ ) today announced that the ... for Renvela(TM) (sevelamer carbonate) for,the control of serum ... Renvela is a next-generation version of Renagel(R) (sevelamer,hydrochloride), ... "Since its approval in 1998, Renagel has ...
... Capital Holdings Asia and,its co-investors today announced that ... Corporation, the world,s largest privately held,crop- protection and ... 250 billion (US$2.2 billion). The sale will culminate ... market private,equity firm with investment teams in Japan, ...
... Oct. 22 AMDL, Inc. (Amex:,ADL), headquartered ... and Jilin, China, through its wholly owned ... biopharma company that,engages in the development, manufacture ... AMDL announced today that its,management will present ...
Cached Biology Technology:
(Date:10/2/2015)... , Oct. 02 2015 ... the "Enforcing the Law Using Biometrics" ... ) has announced the addition of the ... their offering. --> Research and Markets ... the "Enforcing the Law Using Biometrics" ...
(Date:9/30/2015)... , Sept. 30, 2015  The U.S. Court of ... another key ruling in favor of Crossmatch ™, ... fingerprint scanner company Suprema and its U.S. partner Mentalix ... a trade provision that declares it unlawful to engage ... infringing two of Crossmatch,s patents, the 5,900,993 patent and ...
(Date:9/29/2015)... is excited to be named one of the first 100 ... announcement was recently made at an invite-only IBM Watson: ... Francisco , where iDAvatars presented a demo of its ... "It is both an honor and a privilege to be ... the cognitive power of IBM Watson in our product, which ...
Breaking Biology News(10 mins):
... Energy (DOE),s Joint BioEnergy Institute (JBEI) have identified a potential ... diesel engines but would be clean, green, renewable and produced ... a JBEI research team engineered strains of two microbes, a ... a member of the terpene class of chemical compounds that ...
... Clemson University researchers recently reported finding a new class ... how cells repair damaged DNA. The finding from Cao,s ... with computational chemist Brian Dominy appeared in the Sept. ... "A new family of deamination repair enzymes in ...
... Five new research projects announced today (27 September) by ... to overcome some of the fundamental limitations of photosynthesis ... the sun. This research could lead to major increases ... of renewable chemicals. Just over 2M has been ...
Cached Biology News:
Bovine Coronary Artery Smooth Muscle Cells (BCASMC) (>500,000 cells)...
RECK (F-20)...
The improved design and new mechanical solutions of Finnpipette Focus Multichannel Plus improves accuracy and precision.In these low volume multichannel pipettes, the super blow-out function ensures ...
NAK/TBK1 (CT) Affinity Purified Polyclonal Antibody...
Biology Products: